This is a preview of subscription content, log in via an institution to check access.
Notes
The CNT was estimated by multiplying the annualised NNT to prevent one HF event by the annual cost of each therapy.
Reference
Hammerman A, et al. Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus. American Journal of Cardiovascular Drugs : 12 Oct 2021. Available from: URL: http://doi.org/10.1007/s40256-021-00506-5
Rights and permissions
About this article
Cite this article
Dapagliflozin good value for money for diabetic patients with reduced LVEF in the USA. PharmacoEcon Outcomes News 891, 9 (2021). https://doi.org/10.1007/s40274-021-08167-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08167-9